Life sciences business OptiBiotix Health plc (AIM: OPTI) has launched its SlimBiome-based GoFigure products on Amazon India, targeting the world's most populous nation and its growing consumer base.
India, with obesity rates at 40.3% and projected to have the largest medium-to-high income population by 2035, offers significant opportunities for weight management products.
GoFigure products will also remain available through Apollo Pharmacies, both in-store and online, as part of a multi-channel strategy to drive growth in high-potential markets. The Amazon launch coincides with a rebranding effort featuring more vibrant packaging and prominent Fossence branding, leveraging consumer trust in Tata's proprietary ingredient.
OptiBiotix, founded in 2012, develops microbiome-modifying compounds addressing obesity, cardiovascular health and diabetes. Its partnerships with over 20 global food and healthcare companies further enhance its position in the wellness market.
Novo Nordisk launches NovoCare Pharmacy to reduce Wegovy costs and expand access
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Hims & Hers acquires Trybe Labs to expand at-home testing capabilities
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
BrainCool secures market approval for BrainCool System in Malaysia
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
Cellipont Bioservices partners with Secretome Therapeutics for cGMP manufacturing
Life Molecular Imaging's [18F]florbetaben receives US FDA Fast Track Designation
OptiBiotix expands into Indian market with Amazon launch
Veralox Therapeutics agrees Nudge Therapeutics acquisition
European Commission approves Evkeeza for children with HoFH aged 6 months and older
HUTCHMED divests non-core joint venture for USD608m
Microtech commences human clinical trial of microsensor platform for heart failure